Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAL0891 in Advanced Solid Tumors and Relapsed/Refractory AML
NCT05768932Phase 1Recruiting
- Sponsor
- SillaJen
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of BAL0891 in solid tumor (advanced stage), triple-negative breast cancer (TNBC), gastric cancer (GC) and 1 more (8 arms), sponsored by SillaJen. Primary endpoints: Adverse Events up to 2 years, Dose-Limiting Toxicities up to 2 years and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
BAL0891
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)gastric cancer (GC)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05768932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768932.